Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report

Abad, Nazir Hashemi; Doulatabad, Najafi Shala; Mohammadi, Ali; Ghafarian Srazi, Hamid Reza
December 2011
Iranian Journal of Psychiatry;Fall2011, Vol. 6 Issue 4, p161
Academic Journal
Case Study
Schizophrenia and various neurological disorders have some signs and symptoms. Visual hallucinations are one of such disorders. The related studies in some diseases for example Parkinson Disease and Lewy Body Dementia indicate that Acetylcholine (Ach) plays a significant role in neuropsychiatric manifestation and its association with visual hallucination; therefore, visual hallucinations occur due to the depletion of Ach. Drug therapies such as Cholinesterase inhibitors (ChEIs) for increasing Ach level may be beneficial in treating visual hallucination. AchEI's have been used in the treatment of visual hallucinations in Dementia and Parkinson's Disease. We thought that a similar Ach depletion may cause visual hallucinations in patients with schizophrenia and may provide a target for drug treatment. We had a patient with schizophrenia whose psychotic symptoms responded to the treatment plan, but her visual hallucination did not. However, the patient's visual hallucination successfully responded to Rivastigmine (AchEI). This case illustrates the use of an AchEI in the treatment of refractory visual hallucinations in a patient with schizophrenia.


Related Articles

  • A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer’s Disease. Tsai, Ping-Huang; Chang, Shih-Chieh; Liu, Fang-Chun; Tsao, Jenho; Wang, Yung-Hung; Lo, Men-Tzung // Computational & Mathematical Methods in Medicine;5/18/2015, Vol. 2015, p1 

    Alzheimer’s disease (AD) is the most common form of dementia. According to one hypothesis, AD is caused by the reduced synthesis of the neurotransmitter acetylcholine. Therefore, acetylcholinesterase (AChE) inhibitors are considered to be an effective therapy. For clinicians, however,...

  • Low Frequency (1 Hz) rTMS Application in the Treatment of Resistant Auditory Hallucinations: A case presentation. Tekin, Atilla; Bakim, Bahadir; Ozdil, Esra; Diyaddin Guleken, Mehmet // Dusunen Adam: Journal of Psychiatry & Neurological Sciences;Sep2013, Vol. 26 Issue 3, p295 

    Auditory hallucinations are clinically important symptoms which are seen in psychotic disorders. They are associated with low social functionality, increased tendency of violence and suicidality. Some of these cases can just partially respond to medical treatment Recently, there have been a...

  • Valproic acid.  // Reactions Weekly;3/26/2011, Issue 1344, p30 

    The article describes the case of a 21-year-old woman who started receiving valproic acid 500 milligrams (mg)/day, titrated up to 750 mg/day within 4 days, for an acute exacerbation of hallucinations and aggressive behaviour.

  • Hallucinations in schizophrenia. White, Adrian // Acupuncture in Medicine;Sep2010, Vol. 28 Issue 3, p156 

    The article presents a summary and commentary on the use of electro-acupuncture to treat auditory hallucinations in schizophrenic patients.

  • Zinbryta Is Approved As Treatment for MS.  // Chain Drug Review;7/25/2016, Vol. 38 Issue 11, p67 

    The article offers news briefs related to pharmaceutical industry on topics including the approval of Zinbryta for multiple sclerosis by the U.S. Food and Drug Administration, availability of Nuplazid as a prescription for hallucination, and norovirus vaccine trial of Takeda Pharmaceutical Co.

  • A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Matsueda, Kei; Hongo, Michio; Tack, Jan; Saito, Youichi; Kato, Hiroki // Gut;Jun2012, Vol. 61 Issue 6, p821 

    Objective To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial Methods A multicentre, randomised, placebocontrolled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of...

  • Efficacy Assessment of Various Anticholinergic Agents Against Topical Sarin-Induced Miosis and Visual Impairment in Rats. Gore, Ariel; Brandeis, Rachel; Egoz, Inbal; Peri, David; Turetz, Joseph; Bloch-Shilderman, Eugenia // Toxicological Sciences;Apr2012, Vol. 126 Issue 2, p515 

    Eye exposure to the organophosphorus (OP) irreversible acetylcholinesterase inhibitor sarin results in long-term miosis and reduction in visual function. Anticholinergic drugs, such as atropine or homatropine, which are used topically in order to counter these effects may produce mydriasis and...

  • Preparation and in vitro and in vivo evaluation of HupA PLGA Microsphere. Liang Ye; Fenghua Fu; Wanhui Liu; Kaoxiang Sun; Youxin Li; Xin Yu; Jie He; Pengfei Yu; Jingwei Tian // Pakistan Journal of Pharmaceutical Sciences;Mar2013, Vol. 26 Issue 2, p315 

    Acetylcholinesterase inhibitors (AChEIs), including Huperzine A (HupA), have been the mainstay of treatment for Alzheimer's disease (AD). However, AChEIs can cause gastrointestinal side effects, which has been related to the high Cmax and short tmax after oral administration. Clinical trials...

  • Vitamin E and Alzheimer's disease. Chapman, John // Australian Journal of Pharmacy;Mar2014, Vol. 95 Issue 1126, p92 

    The article focuses on the results of an investigation into the effectiveness of vitamin E and memantine in slowing the progression of mild-to-moderate Alzheimer's disease in patients receiving acetylcholinesterase inhibitor. Topics discussed include the slower functional decline observed in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics